Anti-inflammatory And Hypolipidemic Effects Of The Modified Fatty Acid Tetradecylthioacetic Acid In Psoriasis--a Pilot Study

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 43
Sex Both Genders
Notes for this study:
A pilot study in persons with mild to moderate (severe excluded) psoriasis (average age of 44, all caucasian), oral ingestion of 1g TTA for 28 days.

Total cholesterol decreased 7.9%, triglycerides by 16.1%, and total fatty acids (serum) by 11.8%; the HDL to LDL ratio increased in favor of HDL, due to a decrease in non-HDL lipoproteins. IL-6, TNF-a, and VCAM-1 decreased for anti-inflammatory effects.

No adverse effects reported, although some parameters (bilirubin, alkaline phosphatase, GGT, leukocyte total) decreased nonsignificantly and within normal range with TTA.
Funding issues for this study:
Two researchers hold stock with the patent holder of TTA, minor but mentionable conflict of interest.